Aslan Pharmaceuticals (ASLN) Gets a Buy Rating from H.C. Wainwright
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals (ASLN), with a price target of $5.00. The company’s shares closed last Tuesday at $2.50, equals to its 52-week high of $2.50.
According to TipRanks.com, Chen is a top 25 analyst with an average return of 75.6% and a 63.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Currently, the analyst consensus on Aslan Pharmaceuticals is a Moderate Buy with an average price target of $5.00.
See today’s analyst top recommended stocks >>
Aslan Pharmaceuticals’ market cap is currently $82.44M and has a P/E ratio of -1.70. The company has a Price to Book ratio of -6.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm’s portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.